Clinical Trial: Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With Schizophrenia

U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT07484204) titled 'Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With Schizophrenia' on March 16.

Brief Summary: The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of AX251 long-acting injectable (LAI) administered as a single dose in patients with schizophrenia. The study will include sequential dose-escalation cohorts to evaluate different dose levels of AX251 LAI.

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: Schizophrenia

Intervention: DRUG: AX251 LAI 45 mg

Cariprazine 45 mg

DRUG: AX251 LAI 90 mg

Cariprazine 90 mg

DRUG: AX251 LAI 135 mg

Caripraz...